Financial Performance - The unaudited revenue of RMH Holdings Limited for the six months ended June 30, 2024, was approximately S$2,357,000, representing an increase of approximately S$1,048,000 or 80.1% compared to S$1,309,000 for the same period in 2023[7]. - The unaudited profit for the same period was approximately S$879,000, an increase of approximately S$3,673,000 or 131.5% compared to a loss of approximately S$2,794,000 for the six months ended June 30, 2023[8]. - Earnings per share for the six months ended June 30, 2024, was 0.08 Singapore cents, while the loss per share for the same period in 2023 was 0.20 Singapore cents[7]. - The Group's profit before tax for the six months ended June 30, 2024, was S$879,000, compared to a loss of S$2,794,000 for the same period in 2023[9]. - Profit for the period increased to S$879,000 compared to a loss of S$2,794,000 in the same period last year, representing a significant turnaround[11]. - Total comprehensive income for the period was S$664,000, recovering from a loss of S$2,661,000 in the previous year[12]. - Basic and diluted earnings per share attributable to owners of the Company improved to 0.08 Singapore cents from a loss of 0.20 Singapore cents[12]. - For the six months ended June 30, 2024, the profit attributable to the owners of the Company was S$965,000, compared to a loss of S$2,699,000 for the same period in 2023, representing a significant turnaround[41]. Revenue Breakdown - Revenue from treatment services was S$621,000, dental services was S$916,000, and trading sales was S$820,000 for the six months ended June 30, 2024[31]. - Revenue from dental services accounted for approximately 38.9% of total revenue, while dermatology aesthetic and treatment services contributed about 26.3%, and trading sales from health products accounted for approximately 34.8%[69]. - Revenue generated from dental services was approximately S$916,000 for the six months ended June 30, 2024[77]. - Revenue from trading sales, primarily from stem cell supplements and other medical products, was approximately S$820,000, representing an increase of approximately S$411,000 compared to S$409,000 for the same period in 2023[78]. Operating Expenses - Employee benefits expense decreased to S$1,119,000 for the six months ended June 30, 2024, from S$1,449,000 in the same period in 2023[9]. - The Group's total operating expenses increased to S$1,822,000 for the six months ended June 30, 2024, from S$1,557,000 in the same period in 2023[9]. - Other operating expenses rose by approximately S$265,000 or 17.0%, from S$1,557,000 for the six months ended June 30, 2023 to S$1,822,000 for the same period in 2024[93]. Cash Flow and Liquidity - Operating cash flows before working capital changes were S$1,720,000, a recovery from a negative cash flow of S$1,749,000 in the previous year[16]. - Cash from operating activities amounted to S$7,260,000, a significant improvement from a cash outflow of S$1,189,000 in the same period last year[16]. - The Group experienced a net increase in cash and cash equivalents of S$447,000 for the six months ended June 30, 2024, compared to a decrease of S$547,000 in the same period of 2023[17]. - For the six months ended June 30, 2024, the Group reported cash and cash equivalents of approximately S$558,000, indicating insufficient liquidity to settle outstanding balances upon immediate repayment requests[20]. - The Group's current liabilities exceeded its current assets by approximately S$18,063,000 as of June 30, 2024[20]. Assets and Liabilities - Non-current assets totaled S$5,729,000 as of June 30, 2024, compared to S$1,008,000 at the end of 2023, indicating substantial growth[13]. - Current liabilities increased to S$21,846,000 from S$15,242,000, leading to net current liabilities of S$18,063,000[13]. - The Company’s total deficit increased to S$17,421,000 as of June 30, 2024, compared to S$12,519,000 at the end of 2023[13]. - Trade receivables increased to S$3,069,000 as of June 30, 2024, from S$2,338,000 in 2023, with an average credit period of 90 days[49]. - The loss allowance for trade receivables was measured at an amount equal to lifetime expected credit losses, reflecting a proactive approach to credit risk management[50]. - Trade payables increased to S$177,000 as of June 30, 2024, compared to S$39,000 at the end of 2023[55]. - Accrued expenses rose significantly to S$5,009,000 from S$781,000, indicating a substantial increase in liabilities[55]. - Other payables reached S$10,600,000 as of June 30, 2024, up from S$8,388,000, primarily due to amounts owed to Singapore Liquidated Subsidiaries[55]. Corporate Governance and Compliance - The company has complied with all applicable code provisions of the Corporate Governance Code during the six months ended June 30, 2024[107]. - The independent non-executive Directors have confirmed that the Controlling Shareholders complied with their non-competition undertakings for the six months ended June 30, 2024[118]. - The Audit Committee has reviewed the Group's unaudited condensed consolidated financial statements for the six months ended June 30, 2024[122]. Strategic Plans and Future Outlook - The Group plans to expedite the collection of trade receivables and other debts to improve liquidity[23]. - The Group aims to streamline existing non-core businesses and assets while expanding into new segments to enhance operational efficiency and reduce costs[23]. - The Group is actively pursuing alternative financing options, including plans to bring in new investors or subscribe for new shares to settle existing debts and fund future operations[25]. - The company plans to focus major resources on the continuous development of dental and dermatology services while maintaining a prudent investment strategy[73]. - The company believes there is significant market potential for dental implant and dermatology services in Mainland China and Hong Kong due to the large population and aging demographics[70]. - The Group will continue to diversify its services and product offerings through mergers and acquisitions, focusing on the medical, health, and aesthetic wellness sectors in Hong Kong, Greater Bay Area, Singapore, and ASEAN[98]. Shareholder Information - As of June 30, 2024, Loh Teck Hiong holds 210,024,000 shares, representing 15.77% of the company's interest[106]. - Li Mingcheng has an interest in 132,968,000 shares, accounting for 9.98% of the company's interest[106]. - The company has adopted a share option scheme on September 22, 2017, granting 60,000,000 share options to ten directors at an exercise price of HK$0.109 per share[109]. - The issued and fully paid shares remained at 1,332,000,000 as of both June 30, 2024, and December 31, 2023, with share capital at S$2,303,000[63].
德斯控股(08437) - 2024 - 中期业绩